Abstract
The widespread use of prostate-specific antigen (PSA) screening has led to an increased incidence of prostate cancer, and the majority of prostate cancer cases are now detected at an early stage (Cooperberg et al. J Urol 170: S21–5, 2003). PSA can be elevated due to a number of noncancer-related conditions including benign prostatic hyperplasia (BPH), inflammation, infection, and trauma. Also, the PSA value fluctuates, and an elevated PSA can normalize on subsequent measurements (Eastham et al. JAMA 289(20): 2695–700, 2003). The lack of PSA specificity becomes especially apparent when evaluating patients with a mildly elevated PSA. Only 25–35 % of men undergoing prostate biopsy in the PSA “gray zone” of 4–10 ng/ml are found to have prostate cancer, leaving behind a significant portion of patients who undergo potentially unnecessary biopsy (Brawer et al. J Urol 150(1): 106–9, 1993; Catalona et al. J Urol 151(5):1283–90, 1994). Though prostate biopsy is generally safe, it is an invasive procedure invoking patient anxiety and can be associated with complications such as pain, bleeding, sepsis, and possibly impotence (Aus et al. Br J Urol 77(6): 851–5, 1996; Rietbergen et al. Urology 49(6): 875–80, 1997; Fujita et al. J Urol 182(6): 2664–9, 2009). Furthermore, infectious complications from prostate biopsy are increasing in prevalence due to fluoroquinolone resistance (Feliciano et al. J Urol 179(3):952–5, 2008). Hence, the challenge facing the referring physician or urologist is to determine the most appropriate candidates for prostate biopsy among patients who present with an abnormal PSA.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cooperberg MR, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170(6 Pt 2):S21–5. discussion S26–7.
Eastham JA, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289(20):2695–700.
Brawer MK, et al. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol. 1993;150(1):106–9.
Catalona WJ, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151(5):1283–90.
Aus G, et al. Infection after transrectal core biopsies of the prostate–risk factors and antibiotic prophylaxis. Br J Urol. 1996;77(6):851–5.
Rietbergen JB, et al. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology. 1997;49(6):875–80.
Fujita K, et al. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol. 2009;182(6):2664–9.
Feliciano J, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy–are fluoroquinolones still effective prophylaxis? J Urol. 2008;179(3):952–5. discussion 955.
Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology. 1989; 33(6):465.
Palou J, Morote J. Elevated serum PSA and acute bacterial prostatitis. Urology. 1990;35(4):373.
Nadler RB, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2 Pt 1):407–13.
Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am. 1997;24(2):283–91.
Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.
Thompson IM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98(16):1128–33.
Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13): 1192–202.
Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis/chronic pelvic pain syndrome. Annu Rev Med. 2006;57:195–206.
Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236–7.
Neal Jr DE, et al. Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate. 1992;20(2):105–11.
Schaeffer AJ, et al. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol. 2005;174(1):161–4.
Anothaisintawee T, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA. 2011; 305(1):78–86.
Nadler RB, et al. Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urology. 2006;67(2):337–42.
Carver BS, et al. The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J Urol. 2003;169(2):589–91.
Simardi LH, et al. Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology. 2004;64(6):1098–101.
Potts JM. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol. 2000;164(5):1550–3.
Bulbul MA, et al. The effect of antibiotics on elevated serum prostate specific antigen in patients with urinary symptoms and negative digital rectal examination: a pilot study. J Med Liban. 2002;50(1–2):23–5.
Bozeman CB, et al. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol. 2002;167(4):1723–6.
Kaygisiz O, et al. Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10 ng/ml. Prostate Cancer Prostatic Dis. 2006;9(3):235–8.
Serretta V, et al. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer Prostatic Dis. 2008;11(2):148–52.
Baltaci S, et al. Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. J Urol. 2009;181(1):128–32.
Kim YJ, et al. Prostate cancer can be detected even in patients with decreased PSA less than 2.5 ng/ml after treatment of chronic prostatitis. Korean J Urol. 2011;52(7):457–60.
Ugurlu O, et al. Impacts of antibiotic and anti-inflammatory therapies on serum prostate-specific antigen levels in the presence of prostatic inflammation: a prospective randomized controlled trial. Urol Int. 2010;84(2):185–90.
Stopiglia RM, et al. Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial. J Urol. 2010;183(3):940–4.
Loeb S. Use of empiric antibiotics in the setting of an increased prostate specific antigen: pro. J Urol. 2011;186(1):17–9.
Ornstein DK, et al. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol. 1997;157(6):2179–82.
Roehrborn CG, et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581–9.
Marks LS, et al. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006;176(3):868–74.
Nickel JC, et al. Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol. 2011;186(4):1313–8.
Andriole GL, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011;185(1): 126–31.
Cohen YC, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99(18):1366–74.
Redman MW, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008;1(3):174–81.
Theoret MR, et al. The risks and benefits of 5 alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(2):97–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gollapudi, K., Aronson, W.J. (2013). Is There a Role for Medications to Reduce the Need for Prostate Biopsy?. In: Jones, J. (eds) Prostate Cancer Diagnosis. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-188-2_9
Download citation
DOI: https://doi.org/10.1007/978-1-62703-188-2_9
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-187-5
Online ISBN: 978-1-62703-188-2
eBook Packages: MedicineMedicine (R0)